替莫唑胺、伊立替康联合贝伐珠单抗治疗儿童DIPG及高级别胶质瘤:西雅图儿童医院经验
该单中心回顾性研究分析了2009至2018年西雅图儿童医院36例接受放疗后替莫唑胺、伊立替康、贝伐珠单抗(TIB)维持治疗的儿童高级别胶质瘤(pHGG)患者,并进行分子分型。结果显示中位无事件生存期(EFS)和总生存期(OS)分别为16.2和20.1个月,DIPG患者生存期更短(EFS 9.3个月,OS 13.3个月),但DIPG生存期较历史单药替莫唑胺延长,pHGG生存期与类似三药方案相当且优于历史药物,但治愈罕见。
要点
- TIB三药维持方案在儿童pHGG中总体可耐受,主要毒性为血小板减少(28%)和恶心呕吐(19%)。
- DIPG患者中位EFS 9.3个月、OS 13.3个月,5年生存率0%,但较历史单药替莫唑胺延长。
- 非DIPG的pHGG患者1、2、5年生存率分别为85%、38%、16%,治愈罕见。
核心结论
- TIB三药方案在儿童pHGG中可耐受,DIPG生存期较历史单药替莫唑胺延长,pHGG生存期与类似三药方案相当且优于历史药物,但治愈罕见。
研究设计与样本
- 单中心回顾性研究,纳入2009至2018年西雅图儿童医院36例接受放疗后TIB维持治疗的儿童pHGG患者,采用Kaplan-Meier法分析生存,并通过靶向DNA测序进行分子分型。
主要发现
- 中位诊断年龄10.9岁(范围18个月至18岁)。
- 在26个基因中检出遗传学改变,包括H3 K27M突变(12例)、H3F3A G34突变(2例)、IDH突变(4例)和高突变特征(4例)。
- 与化疗延迟或调整相关的副作用包括血小板减少(28%)和恶心/呕吐(19%),替莫唑胺剂量最常被调整。
- 中位EFS和OS分别为16.2和20.1个月;DIPG患者分别为9.3和13.3个月。
临床怎么用
- 对于儿童pHGG,尤其是DIPG,可考虑在放疗后使用TIB三药维持方案,但需监测血小板减少和恶心呕吐等毒性。
- 该方案治愈率低,应优先考虑将患者纳入新药联合标准治疗的临床试验。
局限性
- 单中心回顾性研究,样本量较小(36例),无对照组,历史比较可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Beyond focal radiation, there is no consensus standard therapy for pediatric high-grade glioma (pHGG) and outcomes remain dismal. We describe the largest molecularly-characterized cohort of children with pHGG treated with a 3-drug maintenance regimen of temozolomide, irinotecan, and bevacizumab (TIB) following radiation. METHODS: We retrospectively reviewed 36 pediatric patients treated with TIB at Seattle Children's Hospital from 2009 to 2018 and analyzed survival using the Kaplan-Meier method. Molecular profiling was performed by targeted DNA sequencing and toxicities, steroid use, and palliative care utilization were evaluated. RESULTS: Median age at diagnosis was 10.9 years (18 months-18 years). Genetic alterations were detected in 26 genes and aligned with recognized molecular subgroups including H3 K27M-mutant (12), H3F3A G34-mutant (2), IDH-mutant (4), and hypermutator profiles (4). Fifteen patients (42%) completed 12 planned cycles of maintenance. Side effects associated with chemotherapy delays or modifications included thrombocytopenia (28%) and nausea/vomiting (19%), with temozolomide dosing most frequently modified. Median event-free survival (EFS) and overall survival (OS) was 16.2 and 20.1 months, with shorter survival seen in DIPG (9.3 and 13.3 months, respectively). Survival at 1, 2, and 5 years was 80%, 10% and 0% for DIPG and 85%, 38%, and 16% for other pHGG. CONCLUSION: Our single-center experience demonstrates tolerability of this 3-drug regimen, with prolonged survival in DIPG compared to historical single-agent temozolomide. pHGG survival was comparable to analogous 3-drug regimens and superior to historical agents; however, cure was rare. Children with pHGG remain excellent candidates for the study of novel therapeutics combined with standard therapy.
引用
- Crotty EE, Leary SES, Geyer JR, et al. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience. J Neurooncol. 2020. PMID: 32556862. doi:10.1007/s11060-020-03558-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。